|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| Patient Selection for Radioligand Therapy: Case Study Discussion |
Amir Iravani, MD, and Evan Yu, MD
Phillip Koo hosts a discussion on patient selection for radioligand therapy (RLT) in prostate cancer, featuring Amir Iravani and Evan Yu. The conversation delves into complex clinical decisions involving advanced prostate cancer management. |
|
|
|
|
|
|
|
|
|
|
| Coordinating & Transitioning Patient Care for Patients Who Receive Lutetium-177 |
Elizabeth Davis
Phillip Koo interviews Elizabeth Davis to discuss the crucial role of care coordination in the lutetium Lu 177 vipivotide tetraxetan (PLUVICTO®) program. Ms. Davis outlines the step-by-step process she follows once a physician decides a patient should receive Lutetium-177 treatment. |
|
|
|
|
|
|
|
|
|
|
| Therapy Resistance and Combination Therapies - "Presentation" |
|
Johannes Czernin, MD
|
| Johannes Czernin explores the challenges of resistance in PSMA-targeted theranostics, advocating for personalized treatments based on dosimetry and strategic combination therapies to enhance efficacy and patient survival. Dr. Czernin calls for a shift in treatment approaches, emphasizing the need for optimized radiation delivery and innovative clinical trials to overcome the limitations observed in current practices.
|
|
|
|
|
|
|
|
|
|
|
|
| What is the Optimal Time for PSMA Radioligand Therapy?
|
| Oliver Sartor, MD
|
| Oliver Sartor explored the optimal timing for PSMA radioligand therapy, considering its effectiveness, side effects, and potential alternatives like castration and chemotherapy. Highlighting trials and retrospective studies, he discussed treating metastatic hormone-sensitive prostate cancer and non-metastatic disease, suggesting early administration to delay adverse effects.
|
|
|
|
|
|
|
|
|
|
|
| Workflow Considerations from the Front Desk to Nursing, Including the Supportive Care Idea: The UCLA/UCSF Experience
|
| Linda Gardner, MSN, RN, VA-BC, and Amanda Morley - RN II
|
| Linda Gardner and Amanda Morley share insights on workflow considerations for radioligand therapy (RLT) centers, emphasizing early stakeholder involvement and continuous communication. From licensing to patient education, their experiences at UCLA and UCSF offer valuable lessons for optimizing care in treating sarcomatoid urothelial bladder cancer.
|
|
|
|
|
|
| Evaluating Clinical Outcomes with Systemic Therapy Given After Progression on PSMA Radioligand Therapy in Patients with mCRPC
|
| Soumaya Labidi, MD |
| Soumaya Labidi presents findings on systemic therapy outcomes post-progression on PSMA radioligand therapy in mCRPC. A retrospective study revealed rare responses to subsequent therapy, with PSA levels impacting survival. Notably, taxane response rates were lower post-PSMA therapy, suggesting the need for prospective trials to optimize treatment sequencing.
|
|
|
|
|
|
Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with 177Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis - Beyond the Abstract
|
| Vishnu Murthy, BA |
| Vishnu Murthy discusses the prognostic value of end-of-treatment PSMA PET/CT (ePET) in mCRPC patients treated with 177Lu-PSMA-617. Findings from a retrospective analysis suggest that patients with new lesions on ePET or a greater than 20% increase in whole-body tumor volume had shorter overall survival. These insights underscore the potential of ePET as a prognostic tool and call for larger prospective trials to validate its role in clinical practice. |
|
|
|
|
|
|
